Key points are not available for this paper at this time.
Although PCSK9 is a target for controlling hypercholesterolemia, our data indicate that upon hepatic damage, patients lacking PCSK9 could be at risk.
Share your take
Add a clinician perspective alongside expert commentary.
Zaid et al. (2008) studied this question.